Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis

[1] Yang X-J(2011)Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial Ann Surg Oncol 18 1575-1581

[2] Huang C-Q(2011)Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial Gynecol Oncol 122 215-220

[3] Suo T(1990)(195)PT NMR kinetic and mechanistic studies of cis-and trans-diamminedichloroplatinum (II) binding to DNA J Am Chem Soc 112 6860-6871

[4] Deraco M(1985)Role of ligand exchange processes in the reaction kinetics of the antitumor drug cis-diamminedichloroplatinum(II) with its targets Cancer Res 45 492-498

[5] Kusamura S(1987)Structural aspects of platinum anticancer drug interactions with DNA Chem Rev 87 1153-1181

[6] Virzì S(2002)Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution Ann Oncol 13 267-272

[7] Bancroft D(2008)Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion Eur J Clin Pharmacol 64 907-911

[8] Lepre C(2005)Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: Influence of protein binding Anticancer Drugs 16 1009-1016

[9] Lippard S(2002)Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: Analysis of pharmacokinetics and of nephrotoxicity Anticancer Res 22 3099-3102

[10] Segal E(1996)Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis Cancer Treat Res 81 15-30

[1] Yang X-J(2011)Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial Ann Surg Oncol 18 1575-1581

[2] Huang C-Q(2011)Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial Gynecol Oncol 122 215-220

[3] Suo T(1990)(195)PT NMR kinetic and mechanistic studies of cis-and trans-diamminedichloroplatinum (II) binding to DNA J Am Chem Soc 112 6860-6871

[4] Deraco M(1985)Role of ligand exchange processes in the reaction kinetics of the antitumor drug cis-diamminedichloroplatinum(II) with its targets Cancer Res 45 492-498

[5] Kusamura S(1987)Structural aspects of platinum anticancer drug interactions with DNA Chem Rev 87 1153-1181

[6] Virzì S(2002)Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution Ann Oncol 13 267-272

[7] Bancroft D(2008)Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion Eur J Clin Pharmacol 64 907-911

[8] Lepre C(2005)Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: Influence of protein binding Anticancer Drugs 16 1009-1016

[9] Lippard S(2002)Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: Analysis of pharmacokinetics and of nephrotoxicity Anticancer Res 22 3099-3102

[10] Segal E(1996)Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis Cancer Treat Res 81 15-30